Grazoprevir/elbasvir: Interim Phase II data

Interim data from 102 treatment-naive patients with HCV genotype 1a or 1b infection in the open-label, U.S. Phase II C-SWIFT trial showed that a once-daily, fixed-dose oral combination of 100 mg grazoprevir and 50 mg elbasvir plus 400 mg oral Sovaldi sofosbuvir for 6 or 8 weeks led to an SVR 4/8 weeks after end of treatment in 80-94.7% of patients. In cirrhotic patients, grazoprevir and elbasvir plus Sovaldi led to an SVR4/8 rate of 80% when dosed for 6 weeks and an SVR4/8 rate of 94.7% when dosed for 8 weeks. In non-cirrhotic patients, grazoprevir and elbasvir plus Sovaldi led to an SVR4/8 rate of 38.7% when dosed for 4 weeks and an SVR4/8 rate of 86.7% when dosed for 6 weeks. All 28 patients who did not achieve an SVR4 or SVR8 relapsed following the end of treatment. The combination was generally well tolerated with headache, fatigue and nausea reported as the most common adverse events. Data were presented at the American Association for the Study of Liver Diseases meeting in Boston. ...